Trieu Vuong's Form 4 filing
Oncotelic Therapeutics, Inc. (OTLC) · filed Jun 20, 2023
- Accession no.
- 0001493152-23-021800
- Filed
- Jun 20, 2023, 12:00 PM ET
- Trade date
- Jun 16, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $2.60K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Trieu VuongCIK 0001587074 | Director, Officer (CHAIRMAN AND CEO), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 16, 2023 | Common Stock | PPurchaseAcquired | +100,000 | $0.026 | +$2,600 | 91,544,217 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
On June 16, 2023, Dr. Trieu purchased 100,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.026.